San Diego – – October 06, 2026 -- Halozyme Therapeutics (Nasdaq: HALO) has expanded its global collaboration and license agreement with argenx, adding two new exclusive targets for its ENHANZE drug-delivery platform and raising the partner's total exclusive target count from six to eight.

San Diego – September 30, 2026 -- Halozyme Therapeutics (Nasdaq: HALO) has appointed James "Jim" Daly to its Board of Directors, returning a veteran biopharmaceutical commercial executive to help steer the company's drug-delivery technology expansion.

San Diego – September 19, 2026 -- Halozyme Therapeutics (Nasdaq: HALO) priced $1.3 billion in convertible senior notes due 2033, upsized from an initially announced $1.05 billion offering, carrying a 1.50% annual coupon.